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Abstract
Endometrial cancer is the most common gynecologic malignancy diagnosed among women in developed countries. One
recent biomarker strongly associated with disease progression and survival is epithelial membrane protein-2 (EMP2), a
tetraspan protein known to associate with and modify surface expression of certain integrin isoforms. In this study, we show
using a xenograft model system that EMP2 expression is necessary for efficient endometrial tumor formation, and we have
started to characterize the mechanism by which EMP2 contributes to this malignant phenotype. In endometrial cancer cells,
the focal adhesion kinase (FAK)/Src pathway appears to regulate migration as measured through wound healing assays.
Manipulation of EMP2 levels in endometrial cancer cells regulates the phosphorylation of FAK and Src, and promotes their
distribution into lipid raft domains. Notably, cells with low levels of EMP2 fail to migrate and poorly form tumors in vivo.
These findings reveal the pivotal role of EMP2 in endometrial cancer carcinogenesis, and suggest that the association of
elevated EMP2 levels with endometrial cancer prognosis may be causally linked to its effect on integrin-mediated signaling.
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Introduction
Endometrial cancer is a significant disease in women with
nearly one out of every thirty-five women developing the disease
over her lifetime [1,2]. In the United States endometrial cancer is
the most common malignancy of the female genital tract. It is
generally accepted to be an endocrine-related neoplasm with a
pronounced impact of sex hormone status, and an increased
incidence with age [3].
One protein associated with the development of endometrial
cancer is epithelial membrane protein-2 (EMP2). EMP2 is a
member of the GAS-3/PMP22 subfamily, which together with
tetraspanins and connexins, comprise the three subfamilies of the
large 4-transmembrane family. In the endometrium, EMP2
functions as a prognostic marker which can help predict patients
who will progress from endometrial hyperplasia to cancer [4]. In
patients with endometrial cancer, EMP2 positive tumors have
been shown to be more aggressive and invasive, and its expression
within tumors correlates with poor prognosis and survival [4,5].
Although the exact role of EMP2 in endometrial cancer remains
poorly defined, EMP2 may function as a trafficking molecule for a
variety of proteins and glycolipids to efficiently transfer from a
post-Golgi endosomal compartment to the plasma membrane.
Accordingly, modulation of EMP2 expression and localization
causes pleiotrophic changes on the plasma membrane of several
classes of molecules, including integrins, MHC class I, and GPI-
linked proteins [6,7,8], and EMP2 appears to mediate trafficking
of these molecules to detergent-insoluble glycosphingolipid-
enriched (DIG) membrane domains. DIG domains are thought
to be important for receptor complexing and resultant signal
transduction (reviewed in [9,10,11]).
In this study, we examine the mechanism by which EMP2
contributes to the etiology of endometrial cancer. Previous studies
have shown that EMP2 selectively interacts with integrins in
endometrial cells [6]. As EMP2 expression also correlates with
tumor invasiveness in patients with endometrial cancer, we
examine if modulation of EMP2 alters integrin-associated
signaling proteins. Specifically, we focus on focal adhesion kinase
(FAK), one of the critical focal adhesion signaling proteins and a
protein that EMP2 has been shown to associate with in other cell
systems [12,13]. In endometrial cancer cells, EMP2 promotes
FAK and Src phosphorylation, and contributes to their localiza-
tion within lipid raft domains. As cell adhesion and spreading is a
crucial step in the formation and invasion cascade of cancer cells,
our results suggest that EMP2 is a critical regulator of metastatic
potential of endometrial cancer cells.
Materials and Methods
Cell lines
The human endometrial adenocarcinoma cell lines HEC-1A
(HTB112, ATCC, Manassas, VA) and Ishikawa (generous gift
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or DMEM media supplemented with 10% fetal calf serum at 37uC
in a humidified 5% CO2. Cell lines were used within 2 months
after resuscitation of frozen aliquots and were authenticated based
on viability, recovery, growth, morphology, and isoenzymology.
Both cell lines were also tested for murine pathogens including
mycoplasma by the Division of Laboratory Animal Medicine at
the University of California, Los Angeles. Cells were passaged
every 3–4 days. Stably transfected HEC-1A cells containing a
human EMP2-GFP fusion protein (48 kD), control GFP, or EMP2
specific ribozyme have been previously described [6]. Endogenous
EMP2 is expressed at 20 kD. Ishikawa cells were infected with a
MSCV-EMP2 or control retrovirus, creating the cell lines
Ishikawa/EMP2 and Ishikawa/V [14]. Infected cells were sorted
by GFP using flow cytometry.
Preparation of Xenografts
Ethical Treatment of Animals Statement. This study was
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The procedures used were approved by the
Animal Research Committee at the University of California, Los
Angeles under protocol #2004-182. All efforts were made to
minimize animal suffering.
Four to six-week-old nude BALB/c female mice were obtained
from Charles River Laboratories (Wilmington, MA) and main-
tained at the University of California, Los Angeles. Animals were
inoculated subcutaneously (s.c.) with 1610
6 HEC-1A/OE, HEC-
1A/V, or HEC-1A/RIBO cells into the right and left shoulder
flanks, respectively. Six mice were used per group. Tumors were
measured twice a week, and tumor volumes were calculated by the
formula p/6 x larger diameter x smaller diameter [15], and data
expressed as mean 6 standard error of the mean (SEM). Two-way
ANOVA was used to evaluate overall differences in the means
between different groups as a function of time, and significance
was calculated using p,0.05. At day 30, tumors were excised,
fixed in formalin, and then processed for hematoxylin and eosin
staining by the Tissue Procurement Laboratory at UCLA.
Immunohistochemistry
Tumor samples were stained with human EMP2 antisera or a
preimmune control. Briefly, for antigen retrieval, sections were
incubated at 95uC for 20 minutes in 0.1 M citrate, pH 6.0. EMP2
expression was detected using rabbit human EMP2 antisera at a
dilution of 1:400 as previously described [5] followed by
visualization using the Vector ABC kit (Vector Labs, Burlingame,
CA) according to the manufacturer’s instructions. DAB staining
was quantified using Photoshop 7 [16].
Proliferation Assays
Cellular Proliferation was monitored using two independent
assays. First, a standard static growth assay was performed as
previously described [6,17]. Briefly, 1610
3 cells were plated in
triplicates in a 96-well plates from 0–7 days. At each indicated day,
cells were stained with toluidine blue, lysed with 2% SDS
(Biowhittaker, Walkersville, MD), and absorbance measured at
595 nm. Each experiment was repeated at least three times, and
groups were compared using an unpaired Student’s t test.
Second, the BrdU Cell Proliferation Assay (EMD Chemicals,
Gibbstown, NJ) was performed as per manufacturer’s instructions.
Briefly, triplicate cultures of 10
4 cells were cultured in a 96-well
plate. Cells were then incubated in DMEM +0.5% FCS overnight
to arrest the cells. Cells were then released in complete media
containing BrdU for 2 or 24 hrs. Cells were then fixed,
permeabilized and the DNA denatured. A detector anti-BrdU
monoclonal antibody was then added and ultimately detected
using a horseradish peroxidase-conjugated goat anti-mouse IgG1.
To determine the amount of incorporated BrdU, a fluorogenic
substrate was added and the absorbance quantitated at both 450
and 595 nm using a spectrophotometer.
Wound healing
10
5 HEC-1A and Ishikawa cells with modulated EMP2
expression were seeded in 35-mm tissue culture dishes. When
cells were confluent, a ‘‘wound’’ was created using a 100-ml
‘‘yellow’’ pipette tip as described [13,18]. Wound healing was
monitored over 48 hrs with a 10x phase contrast objective, and
images were collected using a Power Shot S80 camera (Canon,
Lake Success, NY). Manual measurements were made to
quantitate the wound healing process. Three independent
experiments were performed, and the results averaged.
In some experiments, inhibitors were added to determine the
contribution of specific pathways to wound healing. Wildtype
HEC-1A or Ishikawa cells were treated with 10 mM of the FAK-
Src small molecule inhibitor PP2 [19] or 5 mM of Akt inhibitor
VIII ([20]; Calbiochem, San Diego, CA), the EGFR inhibitor
Erlotinib ([21]; 10 mM, Genentech), or the Src family tyrosine
kinase inhibitor Dasatinib ([22]; 10 nM, Bristol-Myers Squibb).
Efficacy of the inhibitors was tested at the manufacturer’s
recommended dosage, and potential toxicity was measured using
trypan-blue exclusion.
Immunoprecipitations
Cells were washed two times with PBS, placed in lysis solution
(1% Nonidet P-40 containing 2 mM phenylmethylsulfonyl fluo-
ride, 10 mg/ml aprotinin, 2 mg/ml, pepstatin, 10 mM iodoaceta-
mide, 0.1 mM EDTA, 0.1 mM EGTA, 10 mM HEPES, and
10 mM KCl), and solubilized for 30 min at 4uC. Lysates were
sonicated for 15 s, and the insoluble materials were pelleted at
10,000 rpm for 10 min. The cell lysates were precleared by
incubation with protein A/G-agarose beads (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA). Precleared, equivalent lysates were
incubated overnight with agarose beads bound to either anti-FAK
rabbit polyclonal antisera (Santa Cruz Biotech), EMP2 antisera, or
isotype rabbit sera. The beads were washed three times in lysis
solution and finally in 50 mM Tris buffer (pH 8). Immune
complexes were eluted from the beads using Laemmli sample
buffer (62.5 mM Tris-Cl, pH 6.8, 10% glycerol, 2% SDS, 0.01%
bromphenol blue, 2% b-mercaptoethanol). As EMP2 contains
multiple glycosylation sites (13), N-linked glycans were cleaved
using peptide N-glycanase (PNGase; New England Biolabs,
Beverly, MA). Eluates were treated as per the manufacturer’s
instructions at 37uC for 2 h and analysed by Western blot analysis
as described below. Blots were digitized using a flatbed scanner
and the band density measured using NIH program Image J.
EMP2:FAK stoichiometry was calculated by dividing the volume
intensities of immunoprecipitation with anti-EMP2 sera over that
with anti-FAK antisera. Experiments were repeated three times,
averaged, and the SEM calculated.
Western blot analysis
Cells were lysed in Laemmli buffer. Proteins were separated by
SDS-PAGE, transferred to a nitrocellulose membrane (Amersham
Biosciences), and stained with Ponceau S (Sigma-Aldrich, St.
Louis, MO) to determine transfer efficiency. Membranes were
blocked with 10% low fat milk in PBS containing 0.1% Tween 20
and probed with EMP2 antisera (1:1000), anti-
576/577p-FAK
(Santa Cruz Biotechnology), anti- total FAK (BD Biosciences),
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416 p-Src (Cell Signaling, Danvers, MA), anti-total Src (Cell
Signaling) or b-actin (Sigma-Aldrich). In some experiments, blots
were probed with anti-Flottillin-2 (BD Biosciences) or anti-EEA1
antibodies (BD Biosciences). Protein bands were visualized using a
horseradish peroxidase-labeled secondary antibody (BD Biosci-
ences; Southern Biotechnology Associates, Birmingham, AL)
followed by chemiluminescence (ECL; Amersham Biosciences).
Band intensities were quantified using the NIH program Image J
as above. To account for loading variability, b-actin was used to
normalize each sample. At least three independent experiments
were performed and, where indicated, the results were evaluated
for statistical significance using a Student’s t-test (unpaired, one-
tail). A level of p,0.05 was considered to be statistically significant.
Immunofluorescence
HEC-1A or Ishikawa cells were plated onto glass coverslips
(Fisher Scientific, Pittsburgh, PA). Cells were fixed in cold
methanol, blocked in 1% normal goat serum, and then incubated
overnight at 4uC with combinations of EMP2, anti-
397p-FAK (BD
Biosciences, 1:250) or a total FAK antibody (BD Biosciences,
1:250) in a humidified chamber. Cells were rinsed with PBS
+0.01% Triton X-100, then incubated (2–4 hours. at RT) with
fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG
(1:50) or rhodamine-conjugated donkey anti-mouse IgG (1:500;
Jackson ImmunoResearch Laboratories, West Grove, PA).
Negative controls included incubation of cells with secondary
antibody alone. Cells were washed in PBS +0.01% Triton, rinsed
briefly with double deionized H20, and mounted in a 3.5% n-
propyl gallate-glycerol solution.
Cell images were captured using a Zeiss LSM 510 confocal
microscope at 600X magnification. The colocalization coefficient
between EMP2 and
397p-FAK or total FAK was determined using
Zeiss LSM 5 PASCAL software (Carl Zeiss MicroImaging GmbH,
Germany), and values represent the relative number of colocaliz-
ing pixels compared to the total number of pixels above threshold.
The mean colocalization coefficient was averaged from at least 3
independent images.
Lipid Raft Fractionation
Cells (5610
7) were harvested and washed in PBS. Cells were
resuspended in Tris-buffered saline (50 mM Tris, pH 7.5, 20 mM
EDTA, complete protease inhibitors and PhosSTOP (both from
Roche Diagnostics, Indianapolis, IN). Cells were lysed by
sonication (Moran and Miceli, 1998; Lusa et al., 2001) and then
dissolved in 1% Triton X-100 or 1% Brij-58 and incubated on ice
for 60 min. The extract was mixed 1:1 with 80% sucrose (40%
final), followed by step overlays with 35 and 5% sucrose, and
centrifuged at 46,000 rpm for 18 h with a Sorvall SW55 rotor
(Global Medical Instrumentation, Albertville, MN). Fractions
(500 ml) were collected from the top of the gradient, and analyzed
by SDS-PAGE. In some cases, samples were treated with PNGase
prior to protein resolution by SDS-PAGE.
Cholesterol depletion was performed as described previously
(Claas et al., 2001). Briefly, cells were washed in PBS to remove
serum. Cells were incubated in DMEM containing 20 mM
methyl-b cyclodextrin (MbCD; Sigma-Aldrich) for 60 min at
37uC. Cells were analyzed by trypan blue exclusion to insure the
lack of toxicity by MbCD before being fractionated as described
above.
Statistical Analysis
All values in the text are mean + SEM. Differences between
means were evaluated using a two-tailed Student’s t test or
ANOVA as indicted. Significant differences were taken at the
p,0.05 level.
Results
EMP2 expression promotes endometrial tumor
development
Endometrial tumors with high levels of EMP2 have been shown
to be more aggressive and correlate with poor clinical outcome [5].
In order to determine if EMP2 expression directly contributed to
tumor formation, we engineered endometrial carcinoma cells to
express modulated levels of the protein (see Methods and
Materials; [6]). 10
6 HEC-1A/EMP2, HEC-1A/V, or HEC-1A/
RIBO were injected s.c. into nude mice, and tumor volume was
then measured over 30 days (Figure 1A). EMP2 overexpression
promoted a two fold increase in tumor growth over HEC-1A/V
cells (Figure 1B) while tumors with reduced EMP2 expression
exhibited a three fold reduction in growth compared to HEC-1A/
EMP2 cells (Figure 1C). Two-way ANOVA indicated that a
statistically significant difference existed in the effect of EMP2 on
tumor growth (p=0.019).
After 30 days, tumors were excised, fixed, and stained by
hemotoxylin/eosin or for EMP2 expression by immunohisto-
chemistry (Figure 1D–F). Hemotoxylin and eosin staining
confirmed the size of the tumors, where HEC-1A/RIBO tumors
were significantly smaller than HEC-1A/EMP2 and HEC-1A/V
tumors. To correlate the change in tumor size with EMP2
expression in vivo, immunohistochemistry was performed. As
expected, two and four fold higher levels of EMP2 were observed
in HEC-1A/EMP2 tumors compared to HEC-1A/V and HEC-
1A/RIBO tumors, respectively (Figure 1D–F).
EMP2 expression does not alter cellular proliferation
One possible mechanism by which EMP2 could contribute to
the malignant phenotype of endometrial cancer cells would be
through alterations in cell proliferation. In order to test this, we
first characterized the growth kinetics of HEC-1A/EMP2, HEC-
1A/V, and HEC-1A/RIBO cells. Equivalent numbers of cells
were plated on day 1 and then manually counted over the next 7
days. No significant differences in total cell numbers were observed
between the three cell lines (Figure 2A). In order to validate this
result, a BrdU cell proliferation assay was performed. Cells were
incubated from 0–24 hours with BrdU to monitor its incorpora-
tion in proliferating cells (Figure 2B). No statistical differences were
found in the kinetics of proliferation between the three cell lines.
EMP2 expression promotes cellular migration
In previous studies examining its expression in clinical
endometrial cancer specimens, EMP2 correlated with invasive
and more aggressive tumors [5]. To determine the contribution of
EMP2 expression to endometrial cancer cell migration, HEC-1A/
EMP2, HEC-1A/V, or HEC-1A/RIBO were grown to conflu-
ence. The cell layer was then wounded by using a sterile pipette
tip, and images of the wound healing response were recorded over
48 hours. As shown in Figure 2C, HEC-1A/EMP2 cells exhibited
a 33.5% increase in wound healing compared to HEC-1A/V
(p=0.03) and a 47.5% increase compared to HEC-1A/RIBO cells
(p=0.01). To confirm that this effect was not specific to HEC-1A
cells, another endometrial cancer cell line was tested. Ishikawa
cells were engineered to over express EMP2, and consistent with
the previous results, Ishikawa/EMP2 exhibited a significant
increase in wound healing over Ishikawa/V cells (Figure 2D;
p=0.02).
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endometrial cancer cell migration, inhibitors were added to
HEC-1A (Figure 2E) or Ishikawa cells (Figure 2F). Cells were
then assayed for their response to migrate and close the wound.
Both inhibition of Akt phosphorylation and EGFR using erlotinib
had no significant effect on both HEC-1A and Ishikawa cell
migration. In contrast, both the FAK-Src small molecule
inhibitor PP2 and the Src family inhibitor dasatinib significantly
Figure 1. Tumor volume is increased in HEC-1A/EMP2 tumors. (A) HEC-1A/EMP2, HEC-1A/V, and HEC-1A/RIBO cells were injected s.c. into
nude mice. Tumor volume was determined using calipers. HEC-1A/EMP2 tumors were larger than tumors injected with HEC-1a/V and HEC-1a/RIBO
cells. Values are averages (6SEM, n=6). Comparison by ANOVA, p,0.05 (B) Representative nude Balb/c mouse displaying HEC-1A/EMP2 and HEC-1A/
V subcutaneous tumors. (C) Representative Balb/c nude mouse displaying HEC-1A/V and HEC-1A/RIBO subcutaneous tumors. At day 30, HEC-1A/
EMP2 (D), HEC-1A/V (E), and HEC-1A/RIBO (F) tumors were excised, fixed, and stained by hematoxylin and eosin or EMP2. H/E Magnification, 40X;
EMP2 Staining Magnification, 400X. Scale bar = 10 mM.
doi:10.1371/journal.pone.0019945.g001
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PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19945Figure 2. EMP2 expression and FAK/Src signaling promote wound healing. (A) HEC-1A/EMP2, HEC-1A/V, and HEC-1A/RIBO cells were
analyzed quantitatively for total cell numbers from 0–7 days or (B) BrdU incorporation after 2 or 24 hours. No significant differences in cellular
proliferation or total cell numbers were observed between the three cell lines. The experiment was repeated at least 3 times with similar results. (C)
HEC-1A/EMP2, HEC-1A/V, or HEC-1A/RIBO cells were grown in a monolayer and then a ‘‘wound’’ created. After 24 h, wound closure was measured.
Experiments were performed at least three times, and the results averaged. Comparison by Student’s t test, * p=0.03; ** p=0.05. (D) The same
experiment was also performed on Ishikawa/EMP2 and Ishikawa/V. Comparison by Student’s t test, * p=0.02. (E) HEC-1A cells were grown to reach a
confluent monolayer. Cells were incubated with the PP2, Dasatinib, Erlotinib, AKTi VIII, or a vehicle control, and a wound created. After 36 h, plates
were imaged, and the percentage of wound closure was calculated. Values are averages (6SEM, n=3). Comparison by Student’s t test, * p,0.05. (F)
The same experiment was also performed on Ishikawa cells. Values are averages (6SEM, n=3). Comparison by Student’s t test, * p,0.05.
doi:10.1371/journal.pone.0019945.g002
EMP2 Activates FAK and Src in Endometrial Cancer
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19945inhibited migration. Importantly, minimal to no toxicity was
observed for any of these inhibitors at the dosages indicated as
determined by trypan blue exclusion (data not shown). These
results suggested that activation of FAK and Src promoted
migration in these cells.
EMP2 correlates with increased FAK and Src
phosphorylation
Given the requirement for the FAK/Src pathway and EMP2
for migration of endometrial cancer cells, we investigated the
relationship of these proteins in HEC-1A and Ishikawa cells.
HEC-1A cells with modulated EMP2 levels were analyzed for
EMP2, FAK, and Src phosphorylation. Total levels of FAK,
Src, and b-Actin were used as controls. HEC-1A/EMP2 cells
express a EMP2-GFP fusion protein at 48 kD and the
endogenous protein at 20 kD. As expected, HEC-1A/RIBO
cells reduced EMP2 expression by two-fold compared with the
vector control. Increased expression of EMP2 resulted in an
increase of activated FAK (phosphorylation at Y-576/577) as
well as activated Src (phosphorylation at Y-416). Conversely, a
reduction of EMP2 expression significantly reduced the
expression of activated FAK and Src (Figure 3A). Similarly,
Figure 3. EMP2 promotes activated FAK and Src expression. Expression of EMP2,
576/577 P-FAK, and
416 P-Src were assessed in (A) HEC-1A/
EMP2, HEC-1A/V and HEC-1A/RIBO cells or (B) Ishikawa/EMP2 and Ishikawa/V cells. Semi-quantitative analysis of
576/577 P-FAK after correction for total
FAK in both HEC-1A (C) and Ishikawa cells (D) from three independent experiments, respectively. b-actin expression was used as an additional loading
control. Comparison by Student’s t test, * p,0.05.
doi:10.1371/journal.pone.0019945.g003
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activated FAK and Src expression, and concordantly, upregula-
tion of EMP2 promoted a two fold increase in the activation of
FAK and Src (Figure 3B).
EMP2 associates with FAK
In order to understand the relationship of FAK and EMP2 in
endometrial cells, confocal microscopy was utilized to compare the
localization of EMP2 and total FAK. In both HEC-1A and
Ishikawa cells, EMP2 was expressed within the cytoplasm and at
the plasma membrane (Figure 4A) [6,23]. FAK displayed a similar
localization pattern within cells, with intense cytoplasmic and
membrane staining, and significant colocalization between EMP2
and FAK was observed. In HEC-1A cells, 34.561.3% of EMP2
colocalized with FAK (Figure 4A), and in Ishikawa cells, 42.668%
colocalization was observed (data not shown).
As microscopy experiments suggested that EMP2 and FAK
resided within similar cellular compartments, we next determined if
the two proteins associated with each other. Immunoprecipitations
were preformed in wildtype HEC-1A cells using 1% Nonidet P-40
to prevent nonspecific hydrophobic interactions [24,25]. Anti-
EMP2 antisera pulled down both EMP2 and FAK (Figure 4B).
Conversely, pull-down with anti-FAK antibodies resulted in
detectable FAK and EMP2 (Figure 4B). We next determined the
proportion of activated FAK that associated with EMP2. Approx-
imately 3563% of activated FAK immunoprecipitated with EMP2.
EMP2 colocalizes with activated FAK
Biochemical studies suggested that a subset of EMP2 immuno-
precipitated with activated FAK. To confirm and extend this
observation, the association of EMP2 and activated FAK was
examined by confocal microscopy. Cells were stained for EMP2
(FITC) and activated FAK (Rhodamine). Approximately 30% of
EMP2 in HEC-1A/EMP2 and 40% of EMP2 in Ishikawa/EMP2
colocalized with activated FAK.(Figure 5A, C). In HEC-1A/V
and Ishikawa/V cells, a two fold reduction in colocalization was
observed. As summarized in Figures 5B and D respectively,
approximately 15 or 20% of EMP2 and activated FAK colocalized
with HEC-1A/V and Ishikwawa/V cells, respectively. Finally,
little colocalization (,5%) was observed between EMP2 and
activated FAK in HEC-1A/RIBO cells.
As elevated EMP2 expression correlated with increased FAK
activation, we next characterized the distribution of p-FAK within
endometrial carcinoma cells. Increased EMP2 levels promoted
activated FAK expression on the plasma membrane, and in contrast,
the EMP2 specific ribozyme appeared to disrupt the organization of
activated FAK (data not shown). HEC-1A/RIBO cells expressed
little activated FAK on the plasma membrane, and instead, p-FAK
was localized within intracellular compartments (data not shown).
EMP2 resides within lipid raft domains
Previous studies have shown that in NIH3T3 fibroblast cells,
EMP2 localized within DIG membrane domains [7]. We thus
hypothesized that EMP2 may create a functional signaling
complex with activated FAK and Src within a DIG lipid raft
membrane domain that regulated the migratory potential of
endometrial cancer cells. To test this hypothesis, we initially
confirmed the localization of EMP2 to lipid raft domains in
wildtype HEC-1A cells. Using both 1% Brij-96 (Figure 6A) or
1% Triton X-100 (Figure 6B), EMP2 localized to the lipid
fractions identified by a common raft protein ganglioside
GM1 [26]. Cholesterol depletion of rafts using methyl-b
cyclodextrin (MbCD) redistributed EMP2 into the non-raft
soluble fractions.
We next determined if modulation of EMP2 expression altered
the distribution of Src, FAK, or their activated forms into lipid raft
domains (Figure 6C). In both HEC-1A/EMP2 and HEC-1A/V,
the distribution of total FAK and Src was similar, with a significant
Figure 4. Total FAK and EMP2 associate with each other. (A)
Cellular images of HEC-1A cells. Cells were stained for EMP2 (FITC) and
total FAK (Rhodamine) expression and imaged using confocal
microscopy. EMP2 and FAK colocalize (yellow) in the cytoplasm and
on the membrane of HEC-1A cells. Scale bar, 20 mM. (B) In order to
assess if EMP2 and FAK immunoprecipitate together, HEC-1A cells were
lysed in 1% NP-40 and an interaction assessed using immunoprecip-
itation/SDS-PAGE analysis. Both a-FAK antibodies and EMP2 antisera
pulled down EMP2, FAK, and
576/577 p-FAK. Normal rabbit antisera
served as the negative isotype control. Experiments were repeated
three times with similar results; a representative image is displayed.
doi:10.1371/journal.pone.0019945.g004
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PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19945Figure 5. EMP2 and activated FAK colocalize. (A) Cellular images of HEC-1A/EMP2 cells stained for confocal microscopy using EMP2 antisera
(FITC) and FAK (activated at tyrosine 397; Rhodamine). (B) Data from at least four separate samples were quantitated using Pascal software to
calculate pixel intensity, and the resultant data was evaluated by Student’s unpaired t-test. Overexpression of EMP2 demonstrated a two-fold increase
in colocalization with p-FAK compared to vector control cells. Less than 5% colocalization was observed in HEC-1A/RIBO cells. Student’s t test,
* p=0.01; ** p=0.0001. Scale bar, 25 mM. (C) Ishikawa/EMP2 cells were stained using EMP2 antisera (FITC) and FAK (activated at tyrosine 397;
Rhodamine) and analyzed by confocal microscopy. (D) Data from at least four separate samples were quantitated and analyzed as above. Student’s t
test, * p=0.01. Scale bar, 25 mM.
doi:10.1371/journal.pone.0019945.g005
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the 1% Triton X-100 detergent soluble fractions (fractions 6–9). In
contrast, decreased levels of total FAK and Src were present in
lipid raft fractions in HEC-1A/RIBO cells. Similar results were
observed with the activated forms of these proteins. Upregulation
of EMP2 expression resulted in increased localization of activated
FAK and Src in lipid rafts. In contrast, reduced EMP2 expression
decreased reduced the levels of activated FAK and eliminated all
activated Src within lipid domains. The redistribution of the FAK-
Src signaling complex appeared to be specific as EMP2 did not
alter the distribution of a known raft protein Flotillin-2 or the
detergent soluble endosome protein EEA1 [27,28].
Figure 6. EMP2 forms a complex with FAK and Src in DIG lipid raft membrane domains. (A) EMP2 expression in HEC-1A lipid raft
membrane domains was verified by Brij-58 insolubility. Cells were lysed in 1% Brij-58 and centrifuged in a sucrose density gradient. Nine fractions
(500 ml each) were collected from the top of the gradient and tested for GM1 by a cholera toxin-HRP dot blot and for EMP2 (,Mr 20 kDa) by using
SDS-PAGE and Western blot analysis. (B) To verify the cholesterol dependence of EMP2 expression within the lipid raft. HEC-1A cells were
preincubated in the presence (+) or absence (–) of MbCB. Cells were lysed in 1% Triton X-100, gradient fractionated, and EMP2 expression detected by
Western blot analysis. (C) HEC-1A/EMP2, HEC-1A/V, and HEC-1A/RIBO cells were lysed in 1% Triton X-100 and centrifuged as above. Samples were
probed by Western blot analysis for EMP2, activated FAK, activated Src, total FAK, total Src, Flotillin-2, and EEA1. Experiments were performed
independently three times with similar results.
doi:10.1371/journal.pone.0019945.g006
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The tetraspan protein EMP2 has been implicated as a
prognostic and survival marker for endometrial cancer [4,5]. In
this study, we examine the tumor growth of endometrial
carcinoma cells with increased or reduced EMP2 expression to
determine the contribution of EMP2 to endometrial cancer
tumorigenicity. Dramatically, HEC-1A tumors with increased
EMP2 expression (HEC-1A/EMP2) exhibit a two fold increase in
tumor volume compared to HEC-1A/V and a three fold increase
compared to cells with reduced EMP2 expression (HEC-1A/
RIBO). Mechanistically, we have started to characterize how
EMP2 expression affects endometrial tumor progression. We
demonstrate that EMP2 is sufficient to activate FAK and its signal
transduction cascade. This effect may be direct as EMP2 and FAK
associate with each other, and a significant proportion of activated
FAK and Src reside within an EMP2-lipid raft complex.
Intact lipid structures have been shown to play critical roles for
proper signal transduction and migration [29,30]. DIG membrane
microdomains are enriched in cholesterol and sphingolipids and
make up two types of membrane compartments. The first are flask-
shaped invaginations called caveolae which contain caveolin-1 [31],
and the second type are flat domains which lack caveolins called
lipid rafts [32]. Endometrial epithelial cells do not have caveolae as
endometrial epithelial cells lack expression of both caveolin-1 and
caveolin-2 (Wadehra and Braun, unpublished results). Our data
supports the conclusion that EMP2 complexes with FAK and Src
leading to enhanced protein phosphorylation, and that this
association occurs within lipid raft microdomains. We predict that
EMP2 expression is necessary to traffic and/or stabilize FAK and
Src phosphorylation within a lipid raft domain with the functional
consequence of this interaction being improved cell migration.
FAK acts as a receptor-proximal protein that bridges the growth-
factor-receptor and integrin signaling pathways [33]. A previous
study has shown that in endometrial epithelial cells, EMP2 regulates
avb3 integrin expression [6], and it is known that in epithelial cells
b3 integrin activation directly leads to Src and FAK phosphoryla-
tionresultinginstablefocaladhesions[34,35].AnalysisofEMP2-b3
integrin-FAK association data suggest that in the endometrium
EMP2 may act as a molecular adaptor for efficient integrin-
mediated FAK activation. In this way, we predict that EMP2 works
to link select integrin isoforms and their associated signaling
modules within DIG lipid raft membrane domains [25,36].
This is similar to the role proposed for other members of the
tetraspan superfamily as several groups have hypothesized that
tetraspanins create a scaffold to regulate signaling, trafficking, and
structural characteristics of their membrane protein constituents
[37,38]. Tetraspanins which have been shown to participate in the
formation of a variety of signaling complexes important for
integrin signaling, B-cell receptor signaling, and fertilization
[24,25]. With regard to integrin signaling, for example, it has
been shown that the interaction of CD151 with integrin a3b1
helps modulate cell adhesion and motility on the extracellular
matrix laminin [39,40], suggesting that the GAS-3 and tetra-
spanins families of proteins may have more in common than was
previously appreciated. Interestingly, tetraspanins are not found in
a lipid raft domains [41]. Thus, it may be that GAS-3 proteins
such as EMP2 help organize lipid raft domain signaling while the
tetraspanins organize non-raft domain signaling.
EMP2 is an early prognostic biomarker in endometrial
hyperplasia, and high expression of EMP2 in endometrial cancer
is associated with a poor prognosis. Similarly, we would predict
that in endometrial cancer, b3 integrin expression will be
upregulated with a concomitant increase in FAK and Src
activation. Clinical data supports this hypothesis. First, b3 integrin
expression has been shown to be upregulated in a number of
cancers, including endometrial [42]. Second, activation of FAK
and Src kinase has been documented in the progression of benign
to malignant endometrium [42,43]. We predict that a better
understanding of the mechanism of EMP2 may help predict
endometrial cancer incidence, prognosis and treatment.
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